Clinico-Pathological Spectrum and Novel Karyotypic Findings in Myelodysplastic Syndrome: Experience of Tertiary Care Center in India

Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta Yadav and Soniya Nityanand

Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Competing interests: The authors have declared that no competing interests exist.

Abstract. Background: Myelodysplastic syndrome (MDS) is a heterogeneous disorder characterized clinically by the presence of cytopenia/s. Limited data are available about the morphological spectrum and cytogenetic profile of Indian MDS patients. The aim of the study was to ascertain the clinico-pathological, morphological and cytogenetic spectrum of Indian MDS patients.

Material and methods: A retrospective analysis of all patients diagnosed with MDS from June 2012 to December 2016 was performed. Their clinical and laboratory data were collated and reviewed.

Results: A total of 150 patients with primary MDS were evaluated with M: F ratio of 1.6:1 and the median age of 55.5 years. 64% patients presented with pancytopenia and 31% with bicytopenia. Morphologically they included MDS-MLD [63 (42%)], MDS-EB 2, [33 (22%)], MDS-EB 1 [32 (21.3%)], MDS-SLD [13 (8.6%)] and two cases (1.4%) each of MDS-SLD-RS, MDS-MLD-RS, and RCC. An abnormal cytogenetic profile was detected in 50% patients. Complex karyotype was observed to be the commonest abnormality (32.5%), and chromosome 7 was the most frequently involved chromosome. Isolated deletion 5q was seen in 6.9% cases. Novel translocations like t(9;22)(q11.2;q34.2), t(1;5)(p22;q33), t(1;12)(p34;p11.2) and t(5;7;9)(q13;q32;p22) were observed in addition to other complex abnormalities. The majority of the patients belonged to the high risk IPSS-R prognostic groups (31.4%); followed by intermediate and very high-risk groups, 29% and 24.4% respectively.

Conclusion: The median age of patients in India is a decade younger than the western population. Complex karyotype was observed to be the commonest cytogenetic abnormality, while the frequency of deletion 5q and trisomy 8 was much lower as compared to the west. The majority of the patients were in high to very high IPSS-R risk categories and seventy percent individuals below 40 years showed abnormal karyotype, indicating that Indian MDS patients have high disease burden at a young age and thus more likelihood for leukemic transformation.

Keywords: MDS, cytogenetic, IPSS-R, India.

Citation: Gupta R., Rahman K., Singh M.K., Kumari S., Yadav G., Nityanand S. Clinico-pathological spectrum and novel karyotypic findings in myelodysplastic syndrome: Experience of tertiary care center in India. Mediterr J Hematol Infect Dis 2017, 9(1): e2017048, DOI: http://dx.doi.org/10.4084/MJHID.2017.048

Published: August 16, 2017 Received: April 22, 2017 Accepted: July 19, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Ruchi Gupta. E-mail: ruchipgi@yahoo.co.in

Introduction. Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorder characterized by morphological dysplasia and ineffective erythropoiesis secondary to immunological dysregulation and apoptosis. The most frequently seen chromosomal...
abnormalities in MDS include the deletion 5q (5q−), trisomy 8 (+8), the deletion 20q (20q−), monosomy of chromosome 7 (−7), the deletion 7q (7q−), monosomy of chromosome 5 (−5) and loss of sex chromosome (-Y). 2 Though these cytogenetic abnormalities are detected in approximately 30-70% individuals, they are one of the most important independent prognostic parameters and have been incorporated into the risk stratification models for predicting prognosis. Risk stratification is traditionally carried out by using international prognostic scoring systems (IPSS) and WHO prognostic system. 3 IPSS is based on the blast percentage, number of cytopenias and cytogenetic subgroups as the most significant independent variables for overall survival (OS) and disease progression, whereas WPSS model incorporated the WHO subgroups, IPSS karyotype, and transfusion requirement. However, none of these scoring systems considered the severity of cytopenias nor did they offer prognostic information for patients with treated or secondary MDS. 3 The impact of cytogenetic on survival in a large dataset of patients with MDS suggested that a distinction into five cytogenetic risk groups provided a more precise prognostication. This lead to the formulation of revised international prognostic scoring system, (IPSS-R) which stratifies MDS into five risk groups based on their depth of cytopenias and inclusion of newer cytogenetic risk stratification for MDS. 4, 5 IPSS-R is based on five different categories of cytogenetics, bone marrow blast percentage (≤2, 3-4, 5-10, and >10%), hemoglobin (≥10, 8-<10, and <8g/dl), platelet count (≥100, 50-99, and <50,000/mm 3) and absolute neutrophil count (≥0.8 and <0.8/mm 3). Though the newer cytogenetic classification takes into account into the majority of the clonal cytogenetic abnormalities, yet approximately 15% patient’s exhibit abnormalities of unknown significance. 5 A recent breakthrough has been DNA sequencing that has helped to find out mutations in nearly 50 genes related to signal transduction, DNA methylation, transcriptional regulation, and RNA splicing. 6 This information has been helpful in the therapeutic management of MDS. Despite the recent advances in the molecular landscape of MDS, 7, 8 which help in understanding the disease biology and heterogeneity, the importance of conventional cytogenetic cannot be over-emphasized for the screening and risk stratification of MDS patients in clinical practice.

There are a limited number of studies describing the cytogenetic profile of MDS from India, 9, 13 and hence this highlights the importance of the present study. It has been previously observed that the disease biology among Indian subcontinent is distinct when compared to the Western population. In this study, we describe the clinico-pathological profile and cytogenetic abnormalities in patients with MDS and categorize them according to the IPSS-R scoring system to assess the disease burden in our cohort of patients.

Materials and Methods.

Patients. This was a retrospective observational study over a period of 4.5 years (June 2012 to December 2016). All cases with a diagnosis of primary untreated cases of MDS were included in the study. Most of the patients were evaluated for refractory cytopenia/s, which was defined as per IPSS-R recommendations. The detailed clinical and investigation profile was traced from patient medical records. The study was approved by the institutional ethics committee.

Morphological examination. May-Grunwald Giemsa (MGG) stained bone marrow aspirate smears were reviewed by two independent pathologists (RG and KR) and diagnosis of MDS was made according to WHO 2016 classification. Perl’s staining for iron stores was also carried out in all the cases to assess for the presence of ring sideroblasts.

Cytogenetic analysis. Heparinized bone marrow samples were collected for conventional karyotyping. The G-banding technique was used, and a minimum of 20 metaphases was analyzed. Karyotypes were described with reference to the International System of Human Cytogenetic Nomenclature (ISCN) 2009 & 2013. The cytogenetic abnormalities were then scored according to IPSS-R cytogenetic categories. Complex karyotype was defined as the presence of three or more structural defects or monosomies. 5 Monosomal karyotype was defined as the presence of at least two autosomal monosomies or a single monosomy associated with at least one additional structural abnormality. 14
Statistical analysis. Statistical analysis was performed using SPSS version 16.0. The difference among groups and correlation studies were analyzed by analysis of variance and Pearson correlation. The level of significance was assigned at p-value <0.05.

Results.

Patient characteristics. A total of 150 patients were analyzed of which 93 were males and 57 females (M: F=1.6:1). The median age was 55.5 (range 2-87 years). Sixty-seven percent patients were below the age of 60 years at presentation. The majority of the patients were being evaluated for unexplained refractory cytopenia/s which included pancytopenia at the presentation in 64% (n=96) patients, bicytopenia in 31.3% (n=47) and isolated anemia and thrombocytopenia in only 3.3 % (n=5) and 1.3% (n=2) patients respectively. The baseline characteristic of the patients is shown in Table 1.

Morphology. The patients were classified according to WHO 2016 into single lineage dysplasia (MDS-SLD, n=13), multilineage dysplasia (MDS-MLD, n = 63), single lineage dysplasia with ring sideroblasts (MDS-SLD-RS, n = 2), multilineage dysplasia with ring sideroblasts (MDS-MLD-RS, n = 2), excess of blast 1 (MDS -EB 1, n = 32), excess of blast 2 (n = 33), two cases of refractory cytopenia of childhood (RCC) and 3 cases of 5q – MDS. Morphologically, 16 patients showed hypoplastic marrow, and the majority of them had excess blasts (57%); with a median blast count of 5%. Clonal abnormalities were detected in 62.5% cases of MDS-SLD, 48.7% cases of MDS-MLD, 44.4% cases of MDS-EB-1, 50% cases of MDS-EB-2 and 78% cases of hypoplastic MDS.

Cytogenetic and risk stratification. Cytogenetic analysis by conventional karyotyping was available in 86/150 (57.3%) cases (Supplementary Table S1). An abnormal karyotype was detected in 43 cases (50%). According to the IPSS-R cytogenetic risk stratification, a significant number of patients exhibited high-risk cytogenetic abnormalities (56.9%). Age adjusted analysis showed an abnormal cytogenetic profile in 70.5% patients aged less than 40 years, in 42.5% patients in the 40-60 years sub-group and 44.8% patients above 60 years old.

The presence of a complex karyotype was found to be the most common cytogenetic abnormality and detected in 32.5% patients. Isolated chromosomal abnormalities were detected in 39.5% (17/43) patients and double abnormalities were present in 16.2% cases. A monosomal karyotype was identified in 15/43 patients (34.9%) patients, of which 73% cases (11/15) had a complex karyotype. Chromosome 7 was the most frequently [32.5% (14/43)] involved chromosome, in the form of monosomy and interstitial deletions and occasional translocation. Isolated monosity seven was seen in only 6.9%
cases. Deletion 20q (del 20q) and deletion 5q (del 5q), in isolation or combination with other chromosomal aberrations, were present in 9.3% and 6.9% patients respectively. The incidence of trisomy 8 was found to be very low (2.3%, 1/43). Interestingly, the presence of t(9;22)(q34;q11.12) was noted in three cases (6.9%), one each of MDS-SLD, MDS-MLD and MDS-EB 2. None of them had any clinical or morphological features suggestive chronic myeloid leukemia (CML). Four patients revealed the presence of chromosomal translocation, unusually reported in MDS, which were 46,XY,t(1;5)(p22;q33), in MDS-SLD, t(1;12)(p34;p11.2) and t(5;7;9)(q13;q32;p22) in a case of MDS-EB 1, and t(1;2)(p36.1;q21) in MDS-EB 2.

The majority of the patients were assigned to the high risk IPSS-R prognostic group (31.4%); followed by intermediate and very high-risk groups, 29% and 24.4% respectively. Only 2.3% patients belonged to the very low-risk category. Age adjusted IPSS-R revealed that 70% patients aged less than <40 years were in the very high and high-risk categories as compared to 51% in the high-risk groups (Supplementary Table S2).

There was no statistically significant correlation between the complex cytogenetic abnormalities and the WHO sub groups and age. The complex karyotype was also detected with equal frequency in both low risk and high-risk morphological categories of MDS and across all age groups.

**Discussion.** Myelodysplastic syndromes are a heterogeneous group of hematological disorders, regarding morphology, cytogenetics and clinical outcome. In comparison to the western countries it has been observed that the median age for MDS is almost a decade lower in India and other Asian countries.9,13,14,15,16 This corroborates with the available demographic profile of Chinese patients with MDS and earlier reports published from Japan.17,18 However, the recent reports from Japan and the Western literature show a preponderance of the disease in old age groups, with the median age being 65-72 years.4,8,19,20 In a multi-institutional study4 of 7012 MDS patients, by Greenberg et al, the average age was found to be 71 years with only 23% patients aged less than 60 years old. This is in contrast to our observation, where more than 67% patients were younger than 60 years.

Clinically, the majority of the patients in our population presented with 2 or 3 lineage cytopenias rather than isolated ones. Morphologically, the incidence of low-risk categories, RA and RARS was only 10%, while high-grade MDS (EB-1 and EB-2) was observed to be 43.4%. The frequency of high-risk MDS is comparable to the data from other Asian countries; however, it is significantly higher (30-40% vs 10-30%) as compared to the western literature.8,19,20 In an attempt to delineate the difference in MDS in the eastern and western countries, a comparative analysis was performed by Matsuda et al in 2005.21 They compared the Japanese and German FAB – RA (refractory anemia) categories, and found that Japanese patients were significantly younger (57 vs 71 years) and had more severe cytopenias than the German patients. An abnormal karyotype was detected in 29% Japanese patients and 53% patients of the German cohort in this subgroup. In our study, the median age of patients in FAB-RA was 52 years, which is comparable to the Japanese cohort, however, the incidence of cytogenetic alterations was very high (62.5 %). The high incidence of cytogenetic abnormalities in RA has also been reported previously from India, where they observed clonal abnormalities in 63.6% patients.9 Another morphological variation worth discussion is the hypoplastic MDS group. The frequency of hypoplastic MDS documented in literature is 8-20%.22,23 In a recent study of 100 hypoplastic MDS patients, it was observed that these patients have statistically significant lower peripheral blood counts, bone marrow blast percentages and a lower incidence of poor-risk cytogenetic abnormalities, as compared to the non hypoplastic groups.24 On the contrary, in our cohort of 9.3% (14/150) patients with hypoplastic MDS, the median blast count was 5% and 78% (7/9) of these patients were found to harbor abnormal karyotype (Supplementary table 2).

Clonal abnormalities were found in 50% cases in our study, which is in concordance with the documented western and Indian literature.9,13,19,20 Importantly, a significantly higher incidence of complex abnormalities and monosomal karyotype was noted in our population (Figure 1) as compared to other published Indian, Chinese4,14 and western data (32.5% vs 6.5-11%, and 34.5% vs 8.1-15%),19,20,25 while the frequency of 5q deletion and trisomy 8 were much lower (6.9 vs 26-30% and 2.3 vs 15-31%, respectively). In recent
Figure 1. Comparative bar diagram highlighting the difference between the common cytogenetic abnormalities reported in different parts of the world. The incidence of complex karyotype, monosomal karyotype and isolated del 5q, monosomy 7/del 7q, trisomy 8 is compared. The incidence of complex and monosomal karyotype is much higher in our study while that of del 5q, monosomy 7/del 7q, trisomy is low.

studies, monosomal karyotype has also been proposed to be a predictor of bad prognosis. Patients with a monosomal karyotype, invariably belong to poor or very poor cytogenetic risk groups and it has been observed the rate of overall mortality and relapse was significantly higher among patients with monosomal karyotype than in those without it. We also detected a few novel cytogenetic abnormalities, mostly in association with complex karyotype. It has been previously observed too, that these rare translocations are usually found in association with other chromosomal alterations and thus their role in disease pathogenesis is unclear. Other rarely reported abnormality includes the presence of Philadelphia chromosome in MDS. Keung MB et al, retrospectively screened 148 Philadelphia positive patients and observed 2% cases of MDS to harbor this mutation. Three patients in our study group showed presence of Philadelphia chromosome or t(9;22)(q34;q11.2) in addition to other cytogenetic alterations. It is intriguing that Armas et al. in their recent review of Philadelphia positive de novo MDS cases have shown that, t(9;22) was the sole abnormality in 50% cases. Additionally, trisomy 8 has been reported in approximately 40% cases along with other complex cytogenetic abnormalities. In our series, all three patients had presented with complaints of cytopenias and past history of packed RBC/platelet transfusion. None of these patients had organomegaly or lymphadenopathy. Morphologically, two of these patients had a normocellular to mildly hypocellular marrow, with evidence of dyspoiesis. The absence of organomegaly, leukocytosis or hypercellular bone marrow and presence of cytopenias with significant dyspoiesis and a complex karyotype favored the diagnosis of MDS over chronic myeloid leukemia in these patients.

As per the IPSS-R prognostic risk stratification, 55.8% of our patients belonged to the high and very high risk categories and only 2.3% and 12.8% of our patients belonged to the very low-risk category and low risk categories respectively. Seventy percent of the individuals aged below 40 years, belonged to the high and very high risk prognostic risk categories. This is in contrast to the available Indian data from southern India and the western data, where IPSS-R risk stratification has been performed.
India, observed majority (73%) of their patients to be aged above 70 years and only 19.2% patients in high risk IPSS-R category.\textsuperscript{13} In a multi centric study by Greenberg P et al, data for 7012 primary untreated MDS patients, from multiple international institutions including Spanish, French, Piemonte (Italy) and Brazilian MDS Registries and the International MDS Risk Analysis Workshop (IMRAW), was compiled and evaluated. IPSS-R stratification revealed 57% patients in very low/low risk and 23% patients in the high/very high risk categories.\textsuperscript{4} Similarly, in a report from the European LeukemiaNet MDS registry, 71.5% and 3.5% patients were assigned in the very low/low risk and high/very high risk categories respectively. These studies clearly highlight the differences in the disease burden in Indian and Western population.\textsuperscript{28}

The inclusion of FISH in the diagnostic armamentarium would aid in identifying additional patients with cryptic abnormalities of chromosome 5 and 7 which might be missed in conventional cytogenetics.\textsuperscript{29} This has been confirmed by Lai et al in a large multi centric study of 2032 chinese patients, where they observed clonal abnormalities by FISH in 23.6% cases with apparently normal cytogenetics. Further, abnormalities detected by FISH were more frequently observed among patients with <5% bone marrow blasts.

In conclusion, the average age of MDS in our country is about a decade less than that reported in western literature. The cytogenetic profile is largely distinct, though there is significant overall heterogeneity in the Indian data, from different parts of the country. Overall, we observed a very high incidence of complex karyotypes and the incidence of isolated del 5q, appears to be much lower as compared to the western data. The majority of our patients belong to high IPSS-R risk categories; indicating the need for early intervention and counseling for stem cell transplantation. A larger population and gene expression profiling based studies with follow up data are required to understand the reasons for the regional variations, genetic mechanism of MDS in our part of the world and their therapeutic implications.

References:
1. Swerdlow S CE, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon.
2. Hasse D. Cytogenetic features in myelodysplastic syndromes. Annals of Hematology 87:515-26. https://doi.org/10.1007/s00277-008-0483-y
3. Jonas BA, Greenberg PL MDS prognostic scoring systems - past, present, and future. Best Pract Res Clin Haematol. 2015 March; 28(1):3-13 https://doi.org/10.1016/j.beha.2014.11.001 PMid:25659725 PMCID:PMC4324398
4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65. https://doi.org/10.1182/blood-2012-03-420489
PMid:22740453 PMCID:PMC4425443
5. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(8):820-9. https://doi.org/10.1200/JCO.2011.35.6394
PMid:22331955 PMCID:PMC4874200
6. Borjas-Gutierrez C, Dominguez-Cruz MD, Gonzalez-Garcia R. Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor. Rev Med Inst Mex Seguro Soc. 2017 Jul-Aug;55(4):481-489. PMid:28591503
7. Kennedy JA, Ebert BL. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. J Clin Oncol. 2017 Mar 20;35(9):968-974. https://doi.org/10.1200/JCO.2016.71.006. PMid:28297619
8. Haferlach T, Negaia Y, Grossmann V, Okuno Y, Bachuer U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014 Feb;28(2):241-7. https://doi.org/10.1038/leu.2013.336
PMid:24220272 PMCID:PMC3918868
9. Varma N, Varma S. Proliferative indices, cytogenetics, immunophenotype and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol Microbiol. 2008 Jan-Mar;51(1):97-101. https://doi.org/10.4103/0377-0230.3940416 PMid:18417875
10. Vundinti BR, Kerketta I, Jijina F, Ghosh K. Cytogenetic study of myelodysplastic syndrome in India. Indian J Med Res. 2009 Aug;130(2):155-9. PMid:19798712
11. Shah NM, Prapajati SG, Adesara RP, Patel AP. An analysis of 30 cases of myelodysplastic syndrome. Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):206-9. https://doi.org/10.4103/0377-0230.3940416 PMid:19332914
12. Chuahy R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res. 2011 Oct;134:452-7. PMid:22089606 PMCID:PMC3372422
13. Narayanan S. Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center. J Blood Med. 2017 Feb 23;8:21. https://doi.org/10.2147/JBM.S129111 PMid:28260966 PMCID:PMC5328424
14. Zhang T, Xu Y, Pan J, Qu H, Wu D, Chen S et al. Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients. Cancer Genet. 2016 Sep 27;209(9):423-429. https://doi.org/10.1016/j.cancergen.2016.06.007 PMid:27423487
15. Demirkan F, Alacacioglu I, Piskin O, Ozcan HG, Akinci B, Ozcan AM et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma. 2007 Jul;48(7):1372-8. https://doi.org/10.1080/10428190701377063 PMid:17613766
16. Qu S, Xu Z, Zhang Y, Qin T, Zhang T, Cui R et al. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. Leukemia & Lymphoma. May 2012; 53(5): 940-946 https://doi.org/10.1080/10428190.2011.634049 PMid:22032534
17. Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res. 1995 Mar;19(3):219-25. https://doi.org/10.1016/0145-2126(94)00135-W
18. Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: Ethnic differences or environmental influence? Leuk Res. 2007 Jan;31(1):103-4. https://doi.org/10.1016/j.leukres.2006.03.007 PMid:16630658
19. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nößlinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007 Dec 15;110(13):4385-95 https://doi.org/10.1182/blood-2007-03-082484 PMid:17726160
20. Kangat N, Patnaik MM, Begna K, Kourelis T, Al-Kali A, Elliott MA. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience with 1000 Patients. Mayo Clin Proc. 2015 Dec;90(12):1623-38 https://doi.org/10.1016/j.mayocp.2015.08.022 PMid:26546107
21. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005 Oct 15;106(8):2633-40 https://doi.org/10.1182/blood-2005-01-0480. PMid:15972453
22. De Souza DC, Fernandez Cibe S, Camargo A, Apa AG, Da Costa ES, Bouzas LF et al. Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. Biomed Res Int. 2014;2014:542395
23. Huang TC, Ko BS, Tang JL, Hou C, Chen CY, Tsay W et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypocellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia. 2008 Mar;22(3):544-50. https://doi.org/10.1038/leu.2004.057 PMid:18094713
24. Yao CY, Hou HA, Lin TY, Lin CC, Chou WC, Tseng MH et al. Clinical characteristics of patients with hypoplastic myelodysplastic syndromes in China. Leuk Res. 2015 May;39(5):530-6. https://doi.org/10.1016/j.leukres.2015.02.005 PMid:27527853 PMCID:PMC3523535
25. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocea B et al. Five- group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012 Aug 16;120(7):1398-408. https://doi.org/10.1182/blood-2012-04-430346 PMid:22767498 PMCID:PMC3478516
26. Kreuz YK, Beatty M, Powell BL, Molnar I, Buss D, Pertnetti M. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia- retrospective study and review of literature. Leuk Res. 2004 Jun;28(6):579-86. https://doi.org/10.1016/S0145-2126(03)00127-9 PMid:15120934
27. Armas A, Chen C, Mims M, Rivero G. Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia. Case Rep Hematol. 2017;2017:450789 https://doi.org/10.1155/2017/450789 PMid:27423487
## Supplementary Table 1: Cytogenetic profile of MDS patients in different subgroups.

| MDS SUBGROUP | KARYOTYPE | NO. OF PATIENTS | % ABNORMAL | % COMPLEX KARYOTYPE |
|--------------|-----------|----------------|------------|---------------------|
| MDS-SLD N=8 | 46XX[20]  | 2              | 62.5       | 40% (2/5)           |
|              | 46XY[20]  | 1              |            |                     |
|              | 41-47.XX,+2,-8,-9,-14,-15,+16,-17,+19,+22 [cp10] | 1 |           |                     |
|              | 46.XY.del(20q) [20] | 1  |           |                     |
|              | 45.XX,-21[20] | 1  |           |                     |
|              | 46.XX.del(11)(q23)[4]/46.XX[16] | 1  |           |                     |
|              | 46.XY.t(15)(p22;q33),-8,t(9;22) (q34;q11.2),+22[15] | 1  |           |                     |
| MDS-MLD N=39| 46 XY [20] | 12             | 48.7       | 14.2 (3/21)         |
|              | 46XX [20] | 6              |            |                     |
|              | 46.XY,-5.del 7(q11.2)-13,+17,-18[20] | 1  |           |                     |
|              | 46.XX, add (19)(q33.3) [20] | 1  |           |                     |
|              | 47.XY,+10.del(20)(q11.2)[04]/46.XY.del(20)(q11.2) [06] | 1  |           |                     |
|              | 45.XX,-7 [20] | 4  |           |                     |
|              | 45.XX,-7.inv(14)[20] | 1  |           |                     |
|              | 46.XY.del(3)(q23)[08]/46.XY[12] | 1  |           |                     |
|              | 46.XY.del(20)(q12) [20] | 1  |           |                     |
|              | 44-46.XX,-18,-19[cp3]/46.XX[17] | 1  |           |                     |
|              | 47.XY,+9[20] | 1  |           |                     |
|              | 45.XY,-9[20] | 1  |           |                     |
|              | 45.XY,-7[12]/46.XY,-7,+21[8] | 1  |           |                     |
|              | 47XY,-7,+21,+22 [20] | 1  |           |                     |
|              | 45.XX,-4.t(9;22)(q34;q11.2) [20] | 1  |           |                     |
|              | 45.XY,-7.del(20)(q12)[10]/45.XY,-7[10] | 1  |           |                     |
|              | 45.XX,-7[15]; 46.XX,-7,+22[05] | 1  |           |                     |
|              | 44-45/46.XX,-15,-16,-19-20[cp08]/46.XY[12] | 1  |           |                     |
| MDS-RS N=1  | 46, XY[20] | 1              |            |                     |
| MDS MLD-RS N=2| 45.XY,-9[20] | 1  |           |                     |
| MDS-EB 1 N=18| 46XY[20] | 1              |            |                     |
|              | 46XX[20]  | 6              | 44.4       | 62.5 (5/8)          |
|              | 46XX[20]  | 4              |            |                     |
|              | 47.XY.del(1)(p34),t(1;12)(p34;p11.2),der(5)add(5)(p15.1),t(5;7;9);(q13;q32;p22),del(12)(p11.2),+14,+mar1,+mar2,+mar3[20] | 1  |           |                     |
|              | Monosomy 5,9,12,14,16,18,20,21[20] | 1  |           |                     |
|              | 46.XX.del(20)(q12) | 1  |           |                     |
|              | 45.XY,-7[06]/46.XY[14] | 1  |           |                     |
|              | 41-43.XY,-7,-13,-16,-17,-18,-19-20,+mar1,+mar2,[cp20] | 1  |           |                     |
|              | 45XY,-9[08]; 46XY[02] | 1  |           |                     |
|              | 42.XX,-9,-16,-17,-19-22[20] | 1  |           |                     |
|              | 50.XY,+13,+19,+21,+21[20] | 1  |           |                     |
| MDS-EB 2 N=12| 46XX[20] | 4              | 50         | 50 (3/6)            |
|              | 46XY [20] | 2              |            |                     |
|              | 43-48.XX,-1,+1,-5,-6,-7,-9,-10,-12,-13,-15,-17,+19,+20,+21,+mar1,+mar2 [cp20] | 1  |           |                     |
|              | 45XY,,-7[20] | 1  |           |                     |
|              | 92<4N>,XXXYY[02]/46.XY[18] | 1  |           |                     |
|              | 44-45.XY,del(4),-5,der(7),-7,-8,t(9;22)(q34;q11.2),-15,+22 | 1  |           |                     |
|              | 44-47.XY,t(12)(p36.1;q21),-2,-4,-5,-6,+13,+18,+mar [20] | 1  |           |                     |
|              | 47.XY, +8[20] | 1  |           |                     |
| RCC N=2      | 46-46.XY,-4,-5,-6,-7,-12,-20,-21,-22,+mar [20] | 1  |           |                     |
| 5Q- N=3      | 46XY [20] | 1              |            |                     |
|              | 46.XY.del(5)[q11.2q15](02)/46.XY[08] | 1  |           |                     |
|              | 46.XY.del(5)[q22] [12] | 1  |           |                     |
|              | 92 <N>,XXX,DEL (5) (Q22) X2 [03] / 46, XX,DEL (5) (Q22)[09]/46.XX[08] | 1  |           |                     |
| HYPOPLASTI   | 46.XY     | 2              | 78%        | 42.8 (3/7)          |
Supplementary Table 2: Age related IPSS-R

| Age (N)  | Very high risk | High risk | Intermediate risk | Low risk | Very low risk |
|----------|----------------|-----------|-------------------|----------|---------------|
| <40 yrs (20) | 7 (35%)        | 7 (35%)   | 5 (25%)           | 1(5%)    | -             |
| 40-60 yrs (37) | 8 (21.6%)    | 11 (29.7%)| 13 (35.1%)        | 5 (13.5%)| -             |
| > 60 yrs (29)  | 6 (20.6%)      | 9 (31.0%) | 7 (24.1%)         | 5 (17.2%)| 2 (6.8%)      |

*Cytogenetics listed again, of cases with hypoplastic MDS*